Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

3406 - BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC)


08 Oct 2016


Breast cancer, metastatic


Melanie Royce


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


M. Royce1, C. Villanueva2, M. Ozguroglu3, T. Bachelot4, S. Azevedo5, F. Melo Cruz6, R. Hegg7, M. Debled8, W.J. Gradishar9, C. Manlius10, A. Ridolfi11, J. Lin12, F. Ringeisen13, F. Cardoso14

Author affiliations

  • 1 Department Of Internal Medicine, University of New Mexico, 87131-0001 - Albuquerque/US
  • 2 Department Of Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, Besançon/FR
  • 3 Medical Oncology, Istanbul University Institute of Oncology, 34093 - Istanbul/TR
  • 4 Service Oncologie Medicale, Centre Léon Bérard, Lyon/FR
  • 5 Oncology, Hospital de Clinicas de Porto Alegre Universidade Federal Do Rs, Porto Alegre/BR
  • 6 Oncology, Instituto Brasileiro de Controle do Cancer, Sao Paulo/BR
  • 7 Department Of Medicine, Hospital Perola Byington, Sao Paulo/BR
  • 8 Medical Oncology, Institute Bergonié, Bordeaux/FR
  • 9 Hematology/oncology, Northwestern University Feinberg School of Medicine, Chicago/US
  • 10 Oncology, Novartis Pharma AG, Basel/CH
  • 11 Oncology, Novartis Pharma S.A.S., Rueil-Malmaison/FR
  • 12 Oncology, Novartis Pharmaceuticals Corporation, East Hanover/US
  • 13 Oncology, Novartis Pharma, CH-4002 - Basel/CH
  • 14 Breast Unit, Champalimaud Clinical Centre, 1400-038 - Lisbon/PT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3406


Efficacy of EVE + exemestane (EXE) in postmenopausal patients (pts) with hormone receptor–positive, HER2− advanced BC progressing on endocrine therapy was established in the phase 3 BOLERO-2 trial (statistically significant 4.6-month increase in median progression-free survival [PFS; local assessment] vs placebo + EXE). BOLERO-4 (NCT01698918) is the first trial to evaluate first-line EVE + LET efficacy and safety in postmenopausal pts with ER + , HER2− metastatic or locally advanced BC. Efficacy of EVE + EXE upon disease progression and a stomatitis therapeutic intervention are secondary objectives.


Postmenopausal pts with ER + , HER2− metastatic or locally advanced BC with no prior advanced disease therapy received EVE 10 mg/day + LET 2.5 mg/day. At disease progression, pts were offered EVE + EXE 25 mg/day until further progression or unacceptable toxicity. Pts with stomatitis completed the Oral Stomatitis Daily Questionnaire and were randomized to local standard of care or alcohol-free dexamethasone 0.5 mg/5 mL oral rinse, where commercially available. Primary endpoint: PFS (first-line setting; local assessment); secondary endpoints: overall response (ORR), clinical benefit (CBR) rate, overall survival, PFS (second line), safety (first and second line), and change in stomatitis severity and duration.


202 pts (median age, 64 years) in 13 countries participated: 194 pts (96%) with metastatic BC and 8 pts (4%) with locally advanced BC. 93 (46%) and 87 (43%) pts received prior hormonal therapy and chemotherapy (neo-/adjuvant setting). The median duration of follow-up was 17.5 months. The median PFS was not yet reached at data cutoff (12 months after the last patient's first visit). The estimated PFS rates (95% CI) were 83.6% (77.3%-88.2%) and 71.4% (64.0%-77.5%) at 6 and 12 months, respectively. ORR and CBR were 42.6% (35.7%-49.7%) and 74.3% (67.7%-80.1%), respectively. The most common adverse events were stomatitis (67.8%), weight loss (42.6%), and diarrhea (36.1%).


EVE combined with LET is an effective regimen in HR + , HER2− advanced BC in the first-line setting.

Clinical trial identification

CRAD001Y24135 Release date: 10 Aug 2015 (Amendment 4)

Legal entity responsible for the study

Novartis Pharmaceuticals Corporation


Novartis Pharmaceuticals Corporation


M. Royce: Research funding from Novartis and Angiochem. C. Villanueva: A consulting or advisory role with Roche, Novartis and Genentech. T. Bachelot: Membership on the board for Roche, Novartis, Zeneca and Pfizer; research funding from Roche and Novartis; speaker fees from Novartis. C. Manlius: Employment with Novartis Pharma AG. A. Ridolfi: Employment with Novartis Pharma S.A.S. J. Lin: Discloses employment with Novartis Pharmaceuticals Corporation. F. Ringeisen: Employment and stock ownership in Novartis Pharma AG. F. Cardoso: Honoraria from Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Merck-Sharp, Merus BV, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Teva. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings